Clinical Trial: Oritavancin for CIED Infections With MDR Gram-positive Cocci

U.S., June 11 -- ClinicalTrials.gov registry received information related to the study (NCT07013552) titled 'Oritavancin for CIED Infections With MDR Gram-positive Cocci' on May 12.

Brief Summary: The study aimed to conduct a randomized, non-inferiority controlled trial to compare the short- and medium-term efficacy and safety of two antibiotic dosage regimens in cardiac implantable electronic devices (CIED) infections with multidrug-resistant Gram-positive cocci: 1) single-dose therapy with a long-half-life antibiotic (oritavancin) vs. standard 7-14 days of therapy with a short-half-life antibiotic (vancomycin) for CIED surgical incision site or pocket infection; and 2) fractionated therapy with a long-half-life antibiotic (oritavancin) a...